Under the terms of the agreement, the financial details of which were not disclosed, Bio-Rad will have the right to develop the heparin binding protein marker for use on its proprietary laboratory instruments worldwide.
Under the terms of the agreement, Bio-Rad will have the right to develop the HBP marker for use on its proprietary laboratory instruments globally. Additional terms of the deal were not disclosed.
With FDA clearance, the test, which had been available outside the US, will now become available in the US.
In PNAS this week: variation patterns in wheat lines, regulatory variation in Capsella grandiflora, and more.
A Rockefeller University researcher is using edited ants to explore complex biological systems, the New York Times writes.
There's a heritable aspect to how much time people spend online, the Los Angeles Times reports.
Stat News reports that Joseph Gulfo is another contender for FDA commissioner.